Results 91 to 100 of about 40,969 (293)
Hydrogel‐forming microneedle (HFMN)‐reservoir patches provide a modular route for controlled transdermal delivery of hydrophilic biomacromolecules. The platform integrates skin‐barrier penetration, sustainable biopolymers, scalable green manufacturing, hydration‐driven transport, model‐cargo validation, and translational quality requirements.
Siddharth Mohanty +4 more
wiley +1 more source
Targeted therapeutics have transformed cancer treatment by selectively eliminating malignant cells while limiting systemic toxicity. L-asparaginase (L-ASNase), which induces metabolic stress by depleting asparagine (Asn), is clinically used for ...
Dinh-Huy Nguyen +7 more
doaj +1 more source
A mitochondrial‐targeted FeCD‐SS31 nanoplatform integrates ROS‐responsive SS31 release with cascade antioxidant Fe3O4/CDs cores to suppress both de novo and existing ROS. By restoring mitochondrial complex integrity and blocking caspase‐1–GSDMD‐N pyroptosis, it reduces neutrophil infiltration and alleviates hepatic ischemia–reperfusion injury, while ...
Qianying Du +12 more
wiley +1 more source
A biomimetic ultrasound‐responsive piRNA delivery nanoparticle platform (piR‐NPs) enables targeted delivery and ultrasound (US)‐triggered release of piR‐1873 in infarcted myocardium. The released piR‐1873 suppresses Usp2‐mediated RIP1/RIP3/MLKL necroptosis, reduces myocardial injury and fibrosis, and promotes cardiac functional recovery, providing a ...
Yajun Zhang +10 more
wiley +1 more source
Versatile nanosystem-based cancer theranostics: design inspiration and predetermined routing
The relevance of personalized medicine, aimed at a more individualized drug therapy, has inspired research into nano-based concerted diagnosis and therapeutics (theranostics).
Opoku-Damoah, Yaw +3 more
core +1 more source
This review presents a pathology‐driven framework unifying nanomedicine across TBI, SCI, and PNI. Epidemiological evidence and comparative single‐cell transcriptomic reanalysis define shared pathological modules, injury‐specific effectors, and therapeutic bottlenecks. Six functional paradigms connect nanomaterial structure and biological fate to injury‐
Mouyuan Sun +12 more
wiley +1 more source
Theranostics vs theratyping or theranostics plus theratyping?
Treating all people with Cystic Fibrosis (pwCF) to the level of benefit achieved by highly efficient CFTR modulator therapies (HEMT) remains a significant challenge. Theratyping and theranostics are two distinct approaches to advance CF treatment.
Margarida D. Amaral, Ines Pankonien
openaire +2 more sources
Tools for controlled selenol delivery are crucial for exploring Se‐related biology and medicine, but compound platforms for triggerable release of CH3SeH remain lacking. Herein, we report the first general triggered platform (TD‐MSe) for efficient cyclization release of CH3SeH in live cells.
Wenfang Liang +7 more
wiley +1 more source
Industry strategies on theranostics: Need for structural alignment
Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information.
Boon, Wouter P C +3 more
core
Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella
Synergistic combinations of immunotherapeutic agents can improve the performance of anti-cancer therapies but may lead to immune-mediated adverse effects. These side-effects can be overcome by using a tumor-specific delivery system.
Dinh-Huy Nguyen +9 more
doaj +1 more source

